女性健康创新

Innovation inWomen’s HealthReport Preview Reach out to MeganScheffelor your SVB point ofcontact to gain access to the full version of the report. June 2026 INNOVATION IN WOMEN’S HEALTH | 2026Executive Summary A Blueprint for the Future of Healthcare Investment trends reflect this expanding scope. While funding peaked in2024 and declined in 2025, capital is more distributed, with strong activityin diagnostics and biopharma—particularly oncology. At the same time,rising early-stage valuations signal sustained investor confidence in thesector’s long-term value. AI companies are currently the biggest winners,making up 20% of all women’s health deals and commanding triple the When we released the first Innovation in Women’s Health report in 2023,the women’s health sector was poorly understood, underreported, andunderestimated. Now, it’s evolving into one of the most dynamic spaces As its full scope becomes clearer, women’s health is becoming a provingground for innovations redefining care delivery for all patients. Oncenarrowly focused on reproductive and sexual health, it has expanded intoa broad, interconnected ecosystem spanning biopharma,healthtech, Artificial intelligence is a critical tool, particularly in diagnostics and riskassessment where nearly 50% of VC-backed companies are using it. AI canenhance early detection and incorporate a wider range of inputs, includingsocial and environmental factors. However, they also expose some criticalchallenges: lack of trust in providers and distrust of AI, entrenched biases in At the heart of this shift is a move away from fragmented, fee-for-servicecare toward integrated, preventive models. Leading startups like MidiHealth and Pomelo Care are emphasizing longitudinal care, patientengagement and early intervention—treating patients holistically overtime rather than addressing isolated conditions. These approaches helpreduce costs and improve patient care in a system where access is still a healthcare data and the historical underrepresentation of women in clinicalresearch. In response, some companies are developing proprietaryalgorithms, while others are developing and expanding real-world data to The changing vision of women’s health has accelerated the shift towardprecision and personalized care, positioning women’s health at the forefrontof more tailored, data-driven treatment. Conditions that disproportionatelyaffect women—such as autoimmune, musculoskeletal andneurodegenerative diseases—or present differently in women—likecardiovascular disease—have historically been overlooked when defining Together, these advances across care models, technology andpersonalization are positioning women’s health at the leading edge ofhealthcare transformation. The lessons emerging from the women’s Megan ScheffelHead of Relationship Management for Life Science & Healthcare Bankingmscheffel@svb.com Report Preview Defining Women’s Health We define women’s health ashealthtech1, biopharma, Dx/Toolsandmedical device companiesthat address care needs for women and individuals with femalebiologies. Diseases thataffect women fall into three categories: conditions that affect women disproportionately, conditions that are unique to women, and conditions that affect women differently. This evolution indefinitions drives a better understanding of how women are affected, where money is invested and where opportunities exist. Healthcare investment was analyzed to identify companies which SOCIAL FACTORS ALSOHAVE AN IMPACT Women’s healthcare goes beyonddiseases and conditions. Social andstructural factors impact the care andhealth needs of women, including: Caregiving for elderly and senior familymembers, as well as pediatricand familycare coordination and decision-making. Lack of access to care, quality ofcare and affordability gaps. Increasing desire for self-advocacyand shared decision-making. Lack of representation in researchand lack of funding for high-impactdiseases We hope you enjoyed your preview of theInnovation in Women’s Health Report 2026 To get the full report, reach out to Megan Scheffel (mscheffel@svb.com) or your SVB point of contact Authors & Acknowledgments Lead Authors NinaKandilianDirector,Healthcare Venture CapitalRelationship Management Megan ScheffelHead of Life Scienceand Healthcaremscheffel@svb.com Adam TweedyHead of Investor Coverage,Life Science and Healthcareatweedy@svb.com Nina is a Director on SVB's Investor Coverage team and managesrelationships with leading healthcare and life science venture capitalfirms. Prior to SVB, Nina was a founding member and head of operationsat theMassChallengeHealthTech accelerator program where she helpedhundreds of healthcare startups scale through key partnerships with Megan Scheffel leads a nationwide team dedicated to serving theunique needs of innovative life science and healthcare companiesat all stages of growth. With 25+ years of experience financinginnovation, she develops creative capital sol